| |
|
 |
 |
The Column Group is a leading venture capital firm dedicated to creating the next generation of biotechnology companies. We will deploy our first fund of approximately $260M to build 8-10 disease-focused drug discovery companies, each with the potential to become a leader in their respective field(s). These companies will be strongly supported by the unique and complementary skill-sets of our team, which includes prominent authorities in the scientific, operational and financial arenas. Typically, we will commit $20M to $30M per company, fostering their growth from seed and early stage to later stages of development. The Column Group seeks to partner with exceptional scientific founders, entrepreneurs, executives and investment organizations that share our vision for building the next generation of drug discovery and development companies. |
 |
| 5AM Ventures is a seed and early-stage venture capital firm focused on building next-generation life science companies. Founded in 2002, 5AM Ventures has over $200 million under management and is actively investing its second fund. As successful former company leaders and established venture capitalists, the 5AM team takes a hands-on approach to company building. In addition to leading investments and contributing as board members of its portfolio companies, 5AM is directly involved in company strategy, management recruiting, business development and fundraising and often takes on short-term operating roles. The firm has offices in Menlo Park, CA and Waltham, MA. |
 |
| Orbimed is the world's largest healthcare-dedicated investment firm, with approximately $5 billion in assets under management. OrbiMed's investment advisory business was founded in 1989 with a vision to invest across the spectrum of healthcare companies: from private start-ups to large multinational companies. OrbiMed manages the Caduceus Private Investments series of venture capital funds and a family of public equity investment funds. |
|
 |
|
